Physician profile
Thomas P Bright
NPI 1205861242
$2,964.12
in general payments reported to CMS, 2019-2025
26 companies · $329 in 2025
The $329 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $198 · 2021: $471 · 2022: $656 · 2023: $455 · 2024: $575 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $654.60 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $593.87 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novartis Pharmaceuticals Corporation | $245.01 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.24 | 2023-2025 | Glassia |
| Insmed, INC. | $153.46 | 2022-2025 | Arikayce |
| Grifols USA, LLC | $146.66 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Jazz Pharmaceuticals INC. | $117.71 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.89 | 2020-2023 | Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $95.71 | 2020-2022 | |
| Harmony Biosciences LLC | $78.98 | 2020-2024 | Wakix |
| Merck Sharp & Dohme LLC | $76.06 | 2021-2024 | Recarbrio, Zerbaxa, Dificid |
| Sunovion Pharmaceuticals INC. | $71.34 | 2019-2020 | |
| Amgen INC. | $66.43 | 2024-2025 | Tezspire |
| Philips North America LLC | $47.85 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $42.71 | 2023-2025 | Acthar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $37.29 | 2023-2024 | Tyvaso |
| Pfizer INC. | $32.05 | 2022-2024 | |
| Pulmonx Corporation | $28.85 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $28.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $26.38 | 2022 | |
| Mayne Pharma Commercial LLC | $25.67 | 2019 | |
| Genzyme Corporation | $24.55 | 2025 | |
| Genentech USA, INC. | $24.53 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $24.33 | 2022 | |
| Mylan Specialty L.P. | $20.43 | 2019 | |
| Inspire Medical Systems, INC. | $16.22 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.